Conference Reports for NATAP

ID Week 2024 October 16-19 Los Angeles, California Back

Tweet

Obeldesivir Reduced SARS-CoV-2 Infectious Titers in the BIRCH Phase 3 Clinical Trial       IDWeek; October 16-19, 2024; Los Angeles, CA, US   Efficacy of the oral nucleoside prodrug GS-5245 (Obeldesivir) against SARS-CoV-2 and coronaviruses with pandemic potential   Oral nucleoside antiviral is progressing toward future pandemic preparedness   Gilead Sciences Statement on Phase 3 Obeldesivir Clinical Trials in COVID-19: BIRCH Study to Stop Enrollment While OAKTREE Study Nears Full Enrollment